Jazz Pharmaceuticals (JAZZ)
NASDAQ: JAZZ
· Real-Time Price · USD
108.23
1.22 (1.14%)
At close: May 29, 2025, 3:59 PM
Jazz Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Defitelio/Defibrotide Revenue | 216.56M | 194.29M | 197.93M | 195.84M | 172.94M | 149.45M | 22.56M | 955.19M | 778.58M | 569.11M | 378.66M |
| Defitelio/Defibrotide Revenue Growth | +11.46% | -1.84% | +1.07% | +13.24% | +15.72% | +562.48% | -97.64% | +22.68% | +36.81% | +50.30% | n/a |
| Epidiolex/Epidyolex Revenue | 972.42M | 736.4M | 463.64M | 6.84M | 17.55M | 18.75M | 33.79M | n/a | n/a | n/a | n/a |
| Epidiolex/Epidyolex Revenue Growth | +32.05% | +58.83% | +6676.45% | -61.02% | -6.37% | -44.52% | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue | 11.47M | 6.64M | 9.8M | 2.35B | 121.41M | 100.83M | 1.19B | n/a | n/a | n/a | n/a |
| Other Products Revenue Growth | +72.68% | -32.20% | -99.58% | +1832.89% | +20.40% | -91.50% | n/a | n/a | n/a | n/a | n/a |
| Product And Services, Product Sales Net Of Deductions Revenue | 3.82B | 3.64B | 3.08B | 121.11M | 1.64B | 1.4B | n/a | n/a | n/a | n/a | n/a |
| Product And Services, Product Sales Net Of Deductions Revenue Growth | +4.94% | +18.27% | +2442.42% | -92.63% | +16.92% | n/a | n/a | n/a | n/a | n/a | n/a |
| Sativex Revenue | 18.88M | 16.82M | 12.71M | 1.74B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sativex Revenue Growth | +12.20% | +32.41% | -99.27% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Oncology Revenue | 1.11B | 127.98M | 134.06M | 15.26M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Oncology Revenue Growth | +768.40% | -4.54% | +778.28% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vyxeos Revenue | 162.59M | 1.02B | 1.27B | 90.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vyxeos Revenue Growth | -84.07% | -19.38% | +1300.56% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Xyrem Revenue | 233.82M | 958.42M | 535.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Xyrem Revenue Growth | -75.60% | +79.05% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Xywav Revenue | 1.47B | 269.91M | 246.81M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Xywav Revenue Growth | +445.81% | +9.36% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zepzelca Revenue | 320.32M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zepzelca Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 312.71M | 239.64M | 230.16M | 175.21M | 150.2M | 125.91M | 122.79M | 106.15M | 103.61M | 126.72M | 61.84M | 38.59M | 6.22M |
| Europe Revenue Growth | +30.49% | +4.12% | +31.36% | +16.65% | +19.29% | +2.54% | +15.68% | +2.44% | -18.23% | +104.90% | +60.26% | +520.02% | n/a |
| Other Countries Revenue | 96.14M | 49.36M | 43.84M | 43.82M | 46.24M | 37.44M | 32.45M | 26.91M | 28.31M | 1.01B | 792.52M | n/a | n/a |
| Other Countries Revenue Growth | +94.77% | +12.59% | +0.05% | -5.24% | +23.53% | +15.37% | +20.59% | -4.96% | -97.19% | +27.11% | n/a | n/a | n/a |
| United States Revenue | 3.66B | 3.37B | 2.82B | 2.14B | 1.97B | 1.73B | 1.46B | 1.35B | 1.19B | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +8.60% | +19.51% | +31.51% | +9.12% | +13.76% | +18.05% | +8.01% | +13.58% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 514.01M | 369.29M | 325.77M | 338.52M | 351.71M | 334.31M | 308.31M | 340.84M | 297.92M | 383.2M | 358.48M | 366.47M | 308.81M | 398.46M | 363.68M | 429.03M | 260.51M | 247.17M | 207.25M | 191.41M | 208.4M | 214.28M | 178.71M | 176.01M | 167.95M | 161.87M | 155.87M | 158.58M | 207.21M | 143.05M | 124.52M | 132.33M | 144.25M | 127.14M | 124.37M | 122.62M | 128.76M | 125.56M | 104.04M | 107.13M | 112.39M |
| Selling, General, and Administrative Revenue Growth | +39.19% | +13.36% | -3.77% | -3.75% | +5.21% | +8.43% | -9.55% | +14.41% | -22.26% | +6.90% | -2.18% | +18.67% | -22.50% | +9.56% | -15.23% | +64.69% | +5.40% | +19.26% | +8.28% | -8.15% | -2.74% | +19.90% | +1.53% | +4.80% | +3.76% | +3.84% | -1.71% | -23.47% | +44.85% | +14.88% | -5.90% | -8.27% | +13.46% | +2.23% | +1.43% | -4.77% | +2.56% | +20.67% | -2.88% | -4.68% | n/a |
| Research and Development Revenue | 180.65M | 240.5M | 199.92M | 220.73M | 222.85M | 216.61M | 234.4M | 209.24M | 189.41M | 172.56M | 148.87M | 139.05M | 129.98M | 155.44M | 141.04M | 132.7M | 76.57M | 91.7M | 78.65M | 78.92M | 86.11M | 97.38M | 79.86M | 62.38M | 60.1M | 56.66M | 51.16M | 56.13M | 62.67M | 66M | 47.36M | 40.16M | 44.93M | 44.16M | 47.8M | 39.09M | 31.25M | 29.45M | 50.78M | 27.83M | 27.18M |
| Research and Development Revenue Growth | -24.88% | +20.30% | -9.43% | -0.95% | +2.88% | -7.59% | +12.03% | +10.47% | +9.77% | +15.91% | +7.06% | +6.97% | -16.38% | +10.22% | +6.29% | +73.29% | -16.50% | +16.60% | -0.35% | -8.34% | -11.58% | +21.95% | +28.01% | +3.79% | +6.09% | +10.74% | -8.86% | -10.43% | -5.04% | +39.34% | +17.94% | -10.62% | +1.74% | -7.61% | +22.27% | +25.08% | +6.10% | -42.00% | +82.46% | +2.40% | n/a |